Huaying Morning News | U.S. stock indices diverged—Dow Jones posted its 9th consecutive gain; Hong Kong's newly listed stocks surged, with several doubling in value within weeks

Pharmaceuticals, infrastructure, and insurance sectors rose: Johnson & Johnson gained over 6%, Freeport-McMoRan rose 3%, while Eli Lilly and Merck each rose over 2%. Abbott (ABT), whose Q2 earnings and revenue exceeded expectations, closed up 4.2%; Zions Bancorporation (ZION), a regional bank whose Q2 earnings beat forecasts, rose nearly 10%. Most popular U.S.-listed Chinese stocks declined, with the Nasdaq Golden Dragon China Index falling 0.62%. iQiyi, Tencent Music, and NIO dropped over 3%, while Bilibili and Weibo fell more than 2%. European equities broadly rose; U.S. wheat futures jumped 11% over three days European stocks rallied on Thursday, buoyed by healthcare shares; the pan-European index rose for the third consecutive day, as did indices in the UK, France, and Italy. Oil prices edged higher—the U.S. and Brent crude benchmarks briefly rose over 1%—supported by declining U.S. crude inventories and robust Chinese crude imports. Gold retreated from a six-week high, trading near $1,970 per ounce. U.S. wheat futures surged then pulled back; they rose over 11% in three days following Russia’s announcement to suspend implementation of the Black Sea Grain Initiative. India imposed an export ban on rice, reigniting concerns about global food security. Hong Kong’s newly listed stocks surged—multiple stocks soared in short term The Hang Seng Index fell 0.13% on Thursday. After opening slightly lower, it briefly turned positive. Speculative enthusiasm reignited among newly listed stocks: Giant Legend surged over 9% shortly after market open—following a 60% two-day rally—and Jay Chou’s concert topped social media trending lists. Yaoshi Bang has risen roughly 100% this month; Zhengwei Group hit a new all-time high, surging over 120% since its January listing; Xin Chuan Planning jumped over 9% right after market open today, gaining 30% over four days. Canggang Railway reached a new record high, surging 3.3-fold since March; Yueyun Transportation has risen over 70% since June, with projected interim net profit attributable to shareholders of no less than RMB 120 million. New listings in Hong Kong and U.S. markets Hong Kong: Recently, Zhonggang Communications filed its prospectus with the Hong Kong Stock Exchange, planning a main-board listing. The company specializes in telecom infrastructure services and ranked third among all telecom network infrastructure construction and maintenance service providers in Jiangxi Province in 2021 by revenue, holding a market share of approximately 3.7%. U.S.: 1) ODD—the parent company of Israel’s fast-growing beauty brand Il Makiage, which debuted Wednesday—rose 35.8% on its first trading day, then climbed over 10% yesterday, closing up more than 5%. 2) Biotech firm Turnstone Biologics Corp. (TSBX) is expected to list tonight; BioNexus Gene Lab Corp. (BGLC), a supplier of raw materials and blood-testing solutions, has again postponed its IPO.

MRD technology makes its debut overseas; IVD enterprises build Chinese brands!

Leveraging a technology named 'Zhengxin’an-MRD', this major Chinese enterprise specializing in tumor genetic testing and non-traditional IVD has attracted the attention of a Nasdaq-listed company—marking the first overseas commercialization of MRD technology and launching a global commercialization plan beginning in Southeast Asia. It is worth noting that such technology export is extremely rare within the IVD sector—and uncommon across the broader healthcare industry—signaling the rise of Chinese medical technology. The protagonist here is Tongshu Genetics, which recently entered into a globally strategic licensing agreement with Nasdaq-listed BioNexus Gene Lab Corp. (BGLC). Under the agreement, Tongshu Genetics licenses its independently developed core technology—the 'Zhengxin’an-MRD' platform for monitoring tumor minimal residual disease (MRD)—to BGLC and its partners. This move makes Tongshu Genetics the first domestic company to successfully export MRD technology overseas, providing strong validation of the international competitiveness of homegrown Chinese innovation. Historically, China’s medical device industry has primarily exported equipment or supplied raw materials; high-value-added cases of innovative technology licensing abroad have been exceedingly scarce. Tongshu Genetics’ successful international rollout of its core MRD monitoring platform represents a breakthrough—from zero to one. To some extent, this demonstrates that China’s frontier innovations in precision oncology diagnosis have advanced beyond 'catching up' and 'running alongside' global leaders, entering a new phase of 'leading' and 'exporting'. Now it’s our turn to say: business knows no borders. Per the agreement, both parties will adopt a phased, systematic global rollout strategy. Phase One will focus initially on ASEAN countries—including Singapore, Malaysia, and Thailand—to secure market access, localize promotion, and implement commercial applications of the VitaGuard™ platform (built upon the 'Zhengxin’an-MRD' technology). Success in this stage will provide critical operational data, clinical feedback, and validation of the commercial model for subsequent phases. The ultimate goal of the collaboration is to jointly advance regulatory approvals for this MRD technology from the U.S. FDA and the European Medicines Agency (EMA), ultimately achieving full-scale commercialization in mainstream Western markets. This 'ASEAN-first, then target Europe and the U.S.' strategy reflects both parties’ firm confidence in the global applicability and value of the 'Zhengxin’an-MRD' technology. Undoubtedly, this recognition stems from technical excellence backed by rigorous scientific validation. The technology employs the internationally leading second-generation 'tumor-naive' detection approach—eliminating the need for matched tumor tissue samples required by conventional methods. Instead, it achieves ultra-sensitive detection of circulating tumor DNA (ctDNA) using only a blood sample, greatly enhancing accessibility and convenience. Underpinning this technical superiority is a rigorous, scientifically grounded clinical validation framework. Based on large-scale, multi-center clinical trial data, the 'Zhengxin’an-MRD' technology demonstrates outstanding clinical performance, with a negative predictive value (NPV) as high as 94.4%. This means that when the test result is negative, patients have an extremely high probability of having no detectable minimal residual disease—providing clinicians with a key, reliable basis for formulating subsequent treatment strategies. Moreover, related studies have received broad recognition from the international academic community, with findings published in multiple high-impact international journals; the cumulative impact factor of these publications exceeds 170.

BioNexus Gene Lab Corp Revenue Breakdown – NASDAQ:BGLC

Jul 27, 2026

BioNexus Gene Lab Corp (NASDAQ:BGLC) reported Malaysia as its primary revenue contributor, generating $5.83 million last year, a decline from $7.46 million the previous year.

TradingView

2026-05-12

BioNexus Gene Lab Corp (BGLC)

2026-06-18

BioNexus Gene Lab Corp (BGLC) Earnings Forecast: Future EPS & Revenue Growth Estimates

2026-06-18

BioNexus Gene Lab Corp (BGLC) Institutional Confidence

2026-06-18

BioNexus Gene Lab Corp (BGLC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

2026-06-18

BioNexus Gene Lab Corp Announces 10-to-1 Merger Stock Split